Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

View Full Paper
Ask AI
Bookmark
Share

Authors

SSStephen J. SchusterVBVeronika BachanováSGSupriya Gupta

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals anti-CD19 CAR T-cell therapy maintains efficacy in CD19-negative large B-cell lymphoma, indicating comparable progression-free survival.

Key Points

  • Patients with CD19-negative large B-cell lymphoma experienced comparable progression-free survival to CD19-positive patients.
  • Using immunohistochemistry, progression-free survival rates showed no significant differences between groups after 18.7 months follow-up.
  • Cytokine release syndrome occurred similarly in CD19-negative and CD19-positive patients, with no statistical significance observed.
  • Findings suggest anti-CD19 CAR T-cell therapy may be viable for CD19-negative large B-cell lymphoma, warranting further research.

Cite This Study

Schuster et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e354https://doi.org/10.1182/blood-2025-957
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience2025 · 1 citations
  2. 2Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies2025
  3. 3Immune recovery and immunologic remodeling after CD19-directed chimeric antigen receptor T cell therapy in autoimmune diseases2025
  4. 4Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  5. 5Human CART22.19 Therapy in Refractory Pediatric B-ALL: Insights from a Named-Patient Cohort2025